Keros Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Keros Therapeutics (KROS).

Price Target Range — 11 Quarters

Analyst Consensus — 13 Analysts

6Buy

7Hold

Consensus RatingBuy# Analysts13Avg. Consensus PT$26Upside to Avg. PT+129.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 4, 2026	Wells Fargo	Benjamin Burnett	PT Cut	Overweight	$20→$18
Aug 4, 2026	Leerink Partners	—	PT Cut	Outperform	$30→$23
Mar 5, 2026	Wells Fargo	Benjamin Burnett	PT Cut	Overweight	$23→$20
Nov 28, 2025	B of A Securities	Jason Zemansky	PT Raise	Neutral	$18→$19
Nov 12, 2025	Oppenheimer	Andreas Argyrides	PT Raise	Outperform	$23→$27
Nov 11, 2025	Wells Fargo	Benjamin Burnett	PT Cut	Overweight	$26→$23
Nov 6, 2025	Wedbush	Yun Zhong	PT Raise	Neutral	$15→$16
Aug 8, 2025	HC Wainwright & Co.	Andres Y. Maldonado	PT Cut	Buy	$25→$20
Jun 10, 2025	B of A Securities	Jason Zemansky	Downgrade	Buy→Neutral	$32→$18
May 30, 2025	Wedbush	Yun Zhong	Maintained	Neutral	$15
May 12, 2025	Scotiabank	Greg Harrison	PT Cut	Sector Outperform	$41→$26
May 8, 2025	HC Wainwright & Co.	Andrew Fein	PT Cut	Buy	$40→$25
Apr 9, 2025	Truist Securities	Srikripa Devarakonda	PT Cut	Buy	$43→$25
Apr 1, 2025	Wedbush	Yun Zhong	Maintained	Neutral	$15
Apr 1, 2025	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$40
Feb 27, 2025	Wells Fargo	Tiago Fauth	PT Cut	Overweight	$28→$26
Feb 27, 2025	HC Wainwright & Co.	Andrew Fein	PT Cut	Buy	$47→$40
Jan 21, 2025	Cantor Fitzgerald	Prakhar Agrawal	Downgrade	Overweight→Neutral	—
Jan 17, 2025	Piper Sandler	Joseph Catanzaro	PT Cut	Overweight	$40→$15
Jan 17, 2025	Wedbush	Andreas Argyrides	Downgrade	Outperform→Neutral	$47→$15

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $18

Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and lowers the price target from $20 to $18.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $20

Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and lowers the price target from $23 to $20.

Benzinga Newsdesk

PRO
B of A Securities Maintains Neutral on Keros Therapeutics, Raises Price Target to $19

B of A Securities analyst Jason Zemansky maintains Keros Therapeutics (NASDAQ:KROS) with a Neutral and raises the price target from $18 to $19.

Benzinga Newsdesk

PRO
Oppenheimer Reiterates Outperform on Keros Therapeutics, Raises Price Target to $27

Oppenheimer analyst Andreas Argyrides reiterates Keros Therapeutics (NASDAQ:KROS) with a Outperform and raises the price target from $23 to $27.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $23

Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and lowers the price target from $26 to $23.

Benzinga Newsdesk

PRO
Wedbush Maintains Neutral on Keros Therapeutics, Raises Price Target to $16

Wedbush analyst Yun Zhong maintains Keros Therapeutics (NASDAQ:KROS) with a Neutral and raises the price target from $15 to $16.

Benzinga Newsdesk

Keros Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Keros Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $18

PRO
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $20

PRO
B of A Securities Maintains Neutral on Keros Therapeutics, Raises Price Target to $19

PRO
Oppenheimer Reiterates Outperform on Keros Therapeutics, Raises Price Target to $27

PRO
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $23

PRO
Wedbush Maintains Neutral on Keros Therapeutics, Raises Price Target to $16

People Also Watch

People Also Watch

Keros Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Keros Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $18

PROWells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $20

PROB of A Securities Maintains Neutral on Keros Therapeutics, Raises Price Target to $19

PROOppenheimer Reiterates Outperform on Keros Therapeutics, Raises Price Target to $27

PROWells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $23

PROWedbush Maintains Neutral on Keros Therapeutics, Raises Price Target to $16

People Also Watch

People Also Watch

PRO
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $18

PRO
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $20

PRO
B of A Securities Maintains Neutral on Keros Therapeutics, Raises Price Target to $19

PRO
Oppenheimer Reiterates Outperform on Keros Therapeutics, Raises Price Target to $27

PRO
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $23

PRO
Wedbush Maintains Neutral on Keros Therapeutics, Raises Price Target to $16